These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25297512)

  • 1. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
    Stingl J; Viviani R
    J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic cytochromes P450 and drugs used in psychiatry.
    Coutts RT; Urichuk LJ
    Cell Mol Neurobiol; 1999 Jun; 19(3):325-54. PubMed ID: 10319191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
    Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
    Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
    Müller DJ; Kekin I; Kao AC; Brandl EJ
    Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and therapeutic prospects in dementia.
    Cacabelos R
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.
    Li D; Pain O; Fabbri C; Wong WLE; Lo CWH; Ripke S; Cattaneo A; Souery D; Dernovsek MZ; Henigsberg N; Hauser J; Lewis G; Mors O; Perroud N; Rietschel M; Uher R; Maier W; Baune BT; Biernacka JM; Bondolfi G; Domschke K; Kato M; Liu YL; Serretti A; Tsai SJ; Weinshilboum R; ; McIntosh AM; Lewis CM
    Transl Psychiatry; 2024 Jul; 14(1):296. PubMed ID: 39025838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of antidepressants: clinical aspects.
    Bertilsson L; Dahl ML; Tybring G
    Acta Psychiatr Scand Suppl; 1997; 391():14-21. PubMed ID: 9265947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the role of drug-metabolising enzymes in antidepressant side effects.
    Hodgson K; Tansey KE; Uher R; Dernovšek MZ; Mors O; Hauser J; Souery D; Maier W; Henigsberg N; Rietschel M; Placentino A; Craig IW; Aitchison KJ; Farmer AE; Dobson RJ; McGuffin P
    Psychopharmacology (Berl); 2015 Jul; 232(14):2609-17. PubMed ID: 25761838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.
    Daly AK
    Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
    Probst-Schendzielorz K; Viviani R; Stingl JC
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
    Sim SC; Kacevska M; Ingelman-Sundberg M
    Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of pharmacogenetics on drug disposition and response.
    Eichelbaum M; Evert B
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):983-5. PubMed ID: 8911746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.
    Calabrò M; Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Serretti A; Crisafulli C
    Eur Neuropsychopharmacol; 2022 Mar; 56():100-111. PubMed ID: 35152032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of pharmacogenetics in psychiatry].
    Skrętkowicz J; Barańska M; Rychlik-Sych M
    Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
    Bertilsson L; Dahl ML; Dalén P; Al-Shurbaji A
    Br J Clin Pharmacol; 2002 Feb; 53(2):111-22. PubMed ID: 11851634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.